Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.
Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Campora L, Dezutter N, de Schrevel N, Fissette L, David MP, Van der Wielen M, Kostanyan L, Hulstrøm V; AReSVi-006 Study Group. Papi A, et al. Among authors: van der wielen m. N Engl J Med. 2023 Feb 16;388(7):595-608. doi: 10.1056/NEJMoa2209604. N Engl J Med. 2023. PMID: 36791160 Clinical Trial.
Combined hepatitis A and B vaccine in elderly.
Van Damme P, Van Herck K, Van der Wielen M. Van Damme P, et al. Among authors: van der wielen m, van herck k. Vaccine. 2004 Jan 2;22(3-4):303-4. doi: 10.1016/j.vaccine.2003.08.011. Vaccine. 2004. PMID: 14670309 No abstract available.
Immunogenicity, reactogenicity and safety of two-dose versus three-dose (standard care) hepatitis B immunisation of healthy adolescents aged 11-15 years: a randomised controlled trial.
Heron L, Selnikova O, Moiseieva A, Van Damme P, van der Wielen M, Levie K, Hoet B, Stoffel M. Heron L, et al. Among authors: van damme p, van der wielen m. Vaccine. 2007 Apr 12;25(15):2817-22. doi: 10.1016/j.vaccine.2006.12.021. Epub 2006 Dec 29. Vaccine. 2007. PMID: 17276552 Clinical Trial.
Second diphtheria booster in adults raises immunity to 92%.
Vellinga A, Van Damme P, Joosens E, van Der Wielen M, Goossens H. Vellinga A, et al. Among authors: van damme p, van der wielen m. BMJ. 2001 Dec 1;323(7324):1308. doi: 10.1136/bmj.323.7324.1308. BMJ. 2001. PMID: 11731400 Free PMC article. No abstract available.
Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile.
Memish ZA, Dbaibo G, Montellano M, Verghese VP, Jain H, Dubey AP, Bianco V, Van der Wielen M, Gatchalian S, Miller JM. Memish ZA, et al. Among authors: van der wielen m. Pediatr Infect Dis J. 2011 Apr;30(4):e56-62. doi: 10.1097/INF.0b013e31820e6e02. Pediatr Infect Dis J. 2011. PMID: 21278617 Clinical Trial.
A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 years.
Vesikari T, Forstén A, Boutriau D, Bianco V, Van der Wielen M, Miller JM. Vesikari T, et al. Among authors: van der wielen m. Hum Vaccin Immunother. 2012 Dec 1;8(12):1882-91. doi: 10.4161/hv.22165. Epub 2012 Oct 2. Hum Vaccin Immunother. 2012. PMID: 23032168 Free PMC article. Clinical Trial.
94 results